Effects of Vitamin D in patients affected by heart failure

A.O. UNIVERSITARIA INTEGRATA DI VERONA0 个研究点目标入组 36 人开始时间: 2012年3月7日最近更新: 2014年5月19日

适应症

试验速览

暂无简介。

•-Written informed consent signed by the patient or by a legally acceptable representative; -Men and women between the ages of 40 and 85 years; -Patients affected by chronic heart failure (Framingham criteria), not in the acute phase, in NYHA class I-II-III-IV secondary to a hypertensive ischemic heart disease or an idiopathic dilated cardiomyopathy, and with echocardiographic assessment of both systolic heart failure (left ventricular ejection fraction = 50%) and heart failure with preserved systolic function (ejection fraction equal or > 45%, evidence of abnormal left ventricular relaxation); -Nutritional deficiency of Vitamin D (VIT D < 30 ng/mL and > 10 ng/mL).
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 36

•-unstable angina; -recent myocardial infarction (within the 6 months prior to enrollment) -cardiogenic shock or hypotension (systolic pressure <100 mm Hg) -uncontrolled hypertension (SBP> 180, DBP> 110); -severe liver disease -severe renal impairment (creatinine> 2mg/dl); -infectious or chronic inflammatory disease; -active cancer or haematological disease; -recent blood transfusion (within 30 days); -abuse of alcohol or drugs in the last year; -severe osteoporosis requiring treatment with bisphosphonates and / or vitamin D; -intake of vitamin D within the 3 months prior to enrollment.

发起方

A.O. UNIVERSITARIA INTEGRATA DI VERONA